Full-Time

Process Data Engineer II

Product Development

Confirmed live in the last 24 hours

Deadline 7/23/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

No salary listed

Mid, Senior

Hyderabad, Telangana, India

In Person

Category
Data Engineering
Data & Analytics
Required Skills
Python
Data Science
R
Git
SQL
Tableau
AWS
Data Analysis
Requirements
  • Bachelor's or Master's degree in analytical, engineering, or in a relevant field such as chemical engineering, or life sciences, with an interest or minor in data science/computer science.
  • Proven experience (typically 3-5 years) in a data and analytics role, including direct development experience.
  • Experience working with large datasets, data visualization tools, statistical software packages and platforms (specifically R, Python, advanced SQL, Domino, AWS, GitHub, dbt, Tableau).
  • Experience with biotech product development and/or manufacturing operations is a significant plus.
  • Experience in the biopharma industry a plus.
Responsibilities
  • Partner with PD scientists and IT team members to develop and implement data engineering solutions that deliver high-quality, contextualized datasets as part of an agile team.
  • Define data requirements, gather and mine large scale structured and unstructured data, and validate data by running various data tools in the Big Data Environment to enable use case development.
  • Collaborate with scientists and engineers to identify data sources and locations, understand data requirements and challenges, and provide data solutions.
  • Collaborate proactively with IT teams to develop and enhance data infrastructure, data pipelines, and analytical tools for efficient data collection, processing, and analysis.
  • Lead the evaluation, implementation, and deployment of emerging tools and processes for analytic data engineering in order to improve productivity.
  • Communicate and translate between life science experts and data engineers.
  • Provide training, guidance, and mentorship to junior analysts and team members when required.
  • Work hours that provide sufficient overlap with standard east coast US working hours.
Desired Qualifications
  • Experience with biotech product development and/or manufacturing operations is a significant plus.
  • Experience in the biopharma industry a plus.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high safety and quality standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, along with a strong commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's partnership with BioNTech could lead to breakthrough cancer immunotherapies.
  • The focus on real-world data can accelerate drug approval processes.
  • Chris Shibutani's appointment may drive strategic innovation and growth.

What critics are saying

  • The antitrust lawsuit over Pomalyst could lead to financial penalties for BMS.
  • The $11.1 billion BioNTech partnership poses financial risks if unsuccessful.
  • Challenges in real-world data quality may hinder competitive advantages.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases, setting it apart in biopharma.
  • The company emphasizes both innovative and generic medicines, broadening its market reach.
  • BMS's commitment to ESG goals enhances its reputation and stakeholder trust.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

The Pharma Letter
Jun 26th, 2025
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst

Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst.

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

Hit Consultant
Jun 10th, 2025
From Raw Records To Real-Time Insights: Climbing Pharma’S Real-World Data Maturity Curve

Viraj Narayanan, CEO at Cornerstone AI Daniel Lane, Head of RWD Strategy & Operations at Bristol Myers SquibbReal-world data (RWD) has become the pharmaceutical industry’s most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and repeatable approach to data quality, as well as a strategic roadmap that moves an organization from minimal use of RWD to a position of true leadership. This journey isn’t simple, but for those committed to navigating it, the competitive advantages are substantial. And, importantly, RWD holds the potential to help bring lifesaving and life-changing medications to market faster and safer than ever before.From Data Collection to MaturityPharma’s growing reliance on RWD has encouraged an influx of partnerships with data aggregators, medical institutions, and digital health platforms. Yet, not all companies are at the same level of maturity in using that data effectively

Devdiscourse
Jun 2nd, 2025
Reuters Health News Summary

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.